



# SANDU PHARMACEUTICALS LTD

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.  
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

**Ref: SPL/CORP-SEC/2018-19/BSE/ 1039**

**Dated: 14.02.2019**

**To,**

Bombay Stock Exchange Ltd,  
Phirojshah Jeejobhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

**Sub: Outcome of the Board Meeting for the FY 2018-19 held on Thursday, 14<sup>th</sup> February 2019 with Scrip Code 524703.**

A Meeting of the Board of Directors of the Company duly convened on **Thursday, 14<sup>th</sup> February 2019 at 5:00 p.m. and Concluded at 6.00 p.m.** at the Corporate Office of the Company at Sandu Nagar, D K Sandu Marg, Chembur, Mumbai inter alia, discussed the following business:-

1. It has approved Unaudited Financial Results for the Quarter ended 31<sup>st</sup> December 2018 along with Limited Review Report.
2. It has Recorded Performance Evaluation done by Nomination and Remuneration Committee.
3. It has Recorded Performance Evaluation done by Independent Director in Independent Directors Meeting.
4. It has Evaluated Performance of Independent Director.
5. It has approved Modifications of Related Party Contract entered into between Sandu Pharmaceuticals Limited and Sandu Brothers Private Limited.

You are requested to kindly take the same on record.

Thanking You

Yours Faithfully

For Sandu Pharmaceuticals Limited

Company Secretary



AN ISO 9001:2008 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.  
Tel.: +91 22 2528 4402 / 3306, Fax: +91 22 2528 2403, E-mail: info@sandu.in, Web: www.sandu.in

CIN:L24233GA1985PLC001587



STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 31/12/18

Particulars	(Rs in Lakhs)					
	Quarter ended			Nine Months ended		Year Ended
	Quarter Ended 31-12- 2018	Corresponding Quarter Ending 30-09-2018	Corresponding Quarter year ended 31-12- 2017	Nine month Ended 31-12- 2018	Corresponding Nine month Ended 31-12- 2017	Previous Year Ended 31-03- 2018 (Audited)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue From Operations	1,418.52	1,221.04	1,116.43	3,750.42	3,543.04	4,915.99
II Other Income	12.43	11.55	0.84	43.38	3.78	12.18
III Total Income (I+II)	1,430.95	1,232.59	1,117.27	3,793.80	4,100.21	4,928.17
IV EXPENSES						
Cost of materials consumed	203.90	204.24	215.00	575.63	483.48	741.93
Purchases of Stock-in-Trade	382.95	355.07	713.57	1,321.11	1,613.81	2,188.82
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	231.29	59.65	(130.71)	90.47	(2.85)	(91.38)
Excise duty on sale of goods						14.40
Employee benefits expense	143.82	217.27	144.47	469.38	395.97	593.64
Finance costs	23.64	33.04	30.43	82.10	94.90	123.10
Depreciation and amortization expense	16.06	16.06	12.59	47.90	36.49	60.24
Other expenses	410.95	316.34	77.46	1,122.48	889.76	1,221.90
<b>Total expenses (IV)</b>	<b>1,412.61</b>	<b>1,201.67</b>	<b>1,062.81</b>	<b>3,709.07</b>	<b>3,511.56</b>	<b>4,852.65</b>
V Profit/(loss) before exceptional items and tax (I- IV)	18.34	30.92	54.46	84.73	35.26	75.52
VI Exceptional Items						
VII Profit/(loss) before tax (V-VI)	18.34	30.92	54.46	84.73	35.26	75.52
VIII Tax expense:						
(1) Current tax	4.77	7.96	16.39	22.03	10.61	19.78
(2) Deferred tax	5.05	1.76		0.70		(0.41)
IX Profit (Loss) for the period from continuing operations (VII-VIII)	8.52	21.20	38.07	62.00	24.65	56.15
X Profit/(loss) for the period (IX+XII)	8.52	21.20	38.07	62.00	24.65	56.15
XI Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss	3.50	(1.42)	9.15	0.44	11.91	13.44
(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.36)	(0.14)		(0.45)		(2.12)
B (i) Items that will be reclassified to profit or loss						
(ii) Income tax relating to items that will be reclassified to profit or loss						
XII Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	11.66	19.64	47.22	61.99	36.56	67.47
XIII Reserves Excluding Revaluation Reserve as per Balance sheet						
XIV Paid Up Equity Capital ( Face Value of Rs 10/- Per share )	708.10	708.10	708.10	708.10	708.10	708.10
XVI Earnings per equity share (for continuing operation):						
(1) Basic	0.12	0.30	0.54	0.88	0.35	0.79
(2) Diluted	0.12	0.30	0.54	0.88	0.35	0.79

Place:- Mumbai  
Date :- 14.02.2019



For Sandu Pharmaceuticals Ltd

Umesh Sandu  
Managing Director


DIN: 01132141

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 14<sup>th</sup> February, 2019. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. On 1<sup>st</sup> April, 2018 the Company has adopted Indian Accounting Standard -115 using the cumulative effect method. Accordingly the comparative information is not restated in the audited/unaudited results for the quarter ended on 31st December, 2018. The adoption of the standard did not have any material impact to the financial results of the Company.
4. Post the applicability of Goods & Service Tax (GST) Act. With effect from 1<sup>st</sup> July, 2017, revenue from operations is disclosed net of GST in accordance with Indian Accounting Standard -18 and schedule III to the Companies Act, 2013 whereas till 30<sup>th</sup> June, 2017, it includes excise duty.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary

Date: - 14/02/2019



For Sandu Pharmaceuticals Ltd

  
Umesh Sandu  
Managing Director  
DIN: 01132141



# Dileep & Prithvi

CHARTERED ACCOUNTANTS

**"LIMITED REVIEW" REPORT ON THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2018**

To,  
**The Board of Directors,  
Sandu Pharmaceuticals Limited,**  
Plot No. 25, 26, 29 & 30,  
Pilerne Industrial Estate, Marra,  
Bardez, Goa-403511.


Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sandu Pharmaceuticals Limited ("the Company") for the quarter ended on December 31, 2018 and year to date from April 1, 2018 to December 31, 2018 (the "Statement"), prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, as amended, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Dileep & Prithvi**

Chartered Accountants

Firm Registration Number : 122290W


  
**Himmat Mali**

(Partner)

Membership Number : 183378

Place: Mumbai

Date: 14<sup>th</sup> February, 2019



**HEAD OFFICE :**

A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road,  
Mumbai - 400 002. • Tel.: +91-22-22071185/ 40031184  
Email : contact@dileepprithvi.com

**BRANCH OFFICE :**

601, Sunshine Building T-39, Opp. Mercedes Auto Hangar,  
Lokhandwala Complex Road, Shastri Nagar, Andheri (W),  
Mumbai - 400 053. • E-mail : prithvi@dileepprithvi.com

**BRANCH OFFICE :**

Office No. 1003-C, 1st Floor, World Trade Centre,  
Near Udhana Darwaja, Ring Road, Surat - 395002. (Gujarat).  
Cell : +91 77679 88047 • E-mail : nikhil@dileepprithvi.com